Estadístiques de Expert consensus on the management of adverse events of Lorlatinib in the treatment of ALK+ advanced non-small cell lung cancer

Visites totals

views
Expert consensus on the management of adverse events of Lorlatinib in the treatment of ALK+ advanced non-small cell lung cancer 7

Visites totals per mes

views
February 2025 0
March 2025 0
April 2025 3
May 2025 1
June 2025 1
July 2025 0
August 2025 2

Visites al fitxer

views
Arriola_cdi_expe.pdf 66